These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35381023)

  • 1. The effect of pandemic prevalence on the reported efficacy of SARS-CoV-2 vaccines.
    Sharma R; Anand A
    PLoS One; 2022; 17(4):e0266271. PubMed ID: 35381023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach.
    Kandala B; Plock N; Chawla A; Largajolli A; Robey S; Watson K; Thatavarti R; Dubey SA; Cheung SYA; de Greef R; Stone J; Sachs JR
    EBioMedicine; 2022 Oct; 84():104264. PubMed ID: 36182824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges.
    Malik JA; Ahmed S; Mir A; Shinde M; Bender O; Alshammari F; Ansari M; Anwar S
    J Infect Public Health; 2022 Feb; 15(2):228-240. PubMed ID: 35042059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis.
    Rotshild V; Hirsh-Raccah B; Miskin I; Muszkat M; Matok I
    Sci Rep; 2021 Nov; 11(1):22777. PubMed ID: 34815503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The way of SARS-CoV-2 vaccine development: success and challenges.
    Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
    Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of approved COVID-19 vaccines.
    Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
    Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccines and decreased transmission of SARS-CoV-2.
    Vitiello A; Ferrara F; Troiano V; La Porta R
    Inflammopharmacology; 2021 Oct; 29(5):1357-1360. PubMed ID: 34279767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.